Other News

CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device

TORONTO, May 17, 2018 (GLOBE NEWSWIRE) — CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial (“CONDI 2”) to further assess […]

Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China

VANCOUVER, May 17, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CRME / TSX: COM), formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess® versus placebo in patients with recent onset atrial fibrillation (AF).  Approximately 240 patients are expected […]

Teleflex to Introduce the New TrapLiner® Catheter in Europe and Showcase the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2018

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio and the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the EuroPCR being held in Paris, France on May 22 – […]

NeuroVasc Technologies, Inc. closes Series B financing of $6.3MM

LAGUNA HILLS, Calif., May 16, 2018 /PRNewswire/ — NeuroVasc Technologies, Inc., a medical device company active in the endovascular field, announced today that it has closed a $6.3MM Series B Preferred Stock financing.  The funding includes multiple investors and was led by ShangBay Capital. NeuroVasc Technologies, Inc. is dedicated to improving treatment of […]

CareTaker Medical Completes $3.4M Investment to Expand Sales of Wireless “Beat-by-Beat” Continuous Blood Pressure and Vital Signs Monitor

CHARLOTTESVILLE, Va., May 16, 2018 /PRNewswire/ — CareTaker Medical, LLC, an innovator in Continuous Non-Invasive Blood Pressure and wireless Vital Signs monitoring today announced completion of a $3.4M investment round led by IrishAngels, KOFA Healthcare and Jaffray Woodriff (executed by his family office, Felton Group, LLC), with participation from both new and existing individual investors.  Proceeds will accelerate the […]

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the […]

Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease

DUBLIN – May 16, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, […]

Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25. During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, ‘real world’ […]